FDA Approves First Biosimilar to Treat Multiple Sclerosis

FDA has approved the first biosimilar to Tysabri (natalizumab) injection for the treatment of relapsing forms of multiple sclerosis.

Source: FDA Center for Drug Evaluation and Research - What's New - August 24, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news